Re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8: The Change in Baseline IMDC Prognostic Category: From the Past, Implications for the Future
- PMID: 28043706
- DOI: 10.1016/j.eururo.2016.12.012
Re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8: The Change in Baseline IMDC Prognostic Category: From the Past, Implications for the Future
Comment in
-
Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8.Eur Urol. 2017 Jun;71(6):e177-e178. doi: 10.1016/j.eururo.2016.12.013. Epub 2016 Dec 29. Eur Urol. 2017. PMID: 28041718 No abstract available.
Comment on
-
Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.Eur Urol. 2017 Jun;71(6):970-978. doi: 10.1016/j.eururo.2016.09.047. Epub 2016 Oct 19. Eur Urol. 2017. PMID: 27771126
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
